Similar clinical characteristics of familial and sporadic inflammatory bowel disease in South Korea

Table 5 Medication types and adverse events in patients with familial and sporadic inflammatory bowel disease n (%)

	Familial CD (n = 17)	Sporadic CD (n = 51)	P value	Familial UC (n = 27)	Sporadic UC (n = 81)	P value
5-ASA	16 (94.1)	50 (98.0)	> 0.999	17 (63.0)	64 (79.0)	0.124
Steroid	7 (41.2)	15 (29.4)	0.551	5 (18.5)	18 (22.2)	0.684
Thiopurines	7 (41.2)	28 (54.9)	0.406	5 (18.5)	11 (13.6)	0.540
Anti-TNF antibodies	3 (17.6)	0 (0.0)	0.014	0 (0.0)	0 (0.0)	-
Suppository
5-ASA	1 (5.9)	0	0.250	3 (11.1)	1 (1.2)	0.047
Steroid	0	2 (3.9)	> 0.999	18 (66.7)	35 (43.2)	0.035
AEs by thiopurine	4 (23.5)	8 (15.7)	0.477	1 (3.7)	6 (7.4)	0.677
Leukopenia	4 (23.5)	7 (13.7)	0.448	1 (3.7)	4 (4.9)	> 0.999
Nausea	0	1 (2.0)	> 0.999	0 (0.0)	0 (0.0)	> 0.999
Arthralgia	0	0	> 0.999	0 (0.0)	1 (1.2)	> 0.999
Skin lesion	0	0	> 0.999	0 (0.0)	1 (1.2)	> 0.999
Pancreatitis	0	0	> 0.999	0	0	> 0.999
Elevation of liver enzyme	0	0	> 0.999	0	0	> 0.999

UC: Ulcerative colitis; CD: Crohn’s disease; ASA: Aminosalicylates; TNF: Tumor necrosis factor; AE: Adverse events.